191 related articles for article (PubMed ID: 8681667)
1. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials.
Rennard SI; Serby CW; Ghafouri M; Johnson PA; Friedman M
Chest; 1996 Jul; 110(1):62-70. PubMed ID: 8681667
[TBL] [Abstract][Full Text] [Related]
2. A multicenter study of nebulized bronchodilator solutions in chronic obstructive pulmonary disease.
Friedman M
Am J Med; 1996 Jan; 100(1A):30S-39S. PubMed ID: 8610715
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of salmeterol xinafoate in the treatment of COPD.
Mahler DA; Donohue JF; Barbee RA; Goldman MD; Gross NJ; Wisniewski ME; Yancey SW; Zakes BA; Rickard KA; Anderson WH
Chest; 1999 Apr; 115(4):957-65. PubMed ID: 10208192
[TBL] [Abstract][Full Text] [Related]
4. Bronchodilator response of advanced lung function parameters depending on COPD severity.
Jarenbäck L; Eriksson G; Peterson S; Ankerst J; Bjermer L; Tufvesson E
Int J Chron Obstruct Pulmon Dis; 2016; 11():2939-2950. PubMed ID: 27932874
[TBL] [Abstract][Full Text] [Related]
5. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease.
Jarvis B; Markham A
Drugs Aging; 2001; 18(6):441-72. PubMed ID: 11419918
[TBL] [Abstract][Full Text] [Related]
6. Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary disease.
Colice GL
Am J Med; 1996 Jan; 100(1A):11S-18S. PubMed ID: 8610712
[TBL] [Abstract][Full Text] [Related]
7. Inhaled short-acting beta2-agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease.
McCrory DC; Brown CD
Cochrane Database Syst Rev; 2001; 2001(2):CD002984. PubMed ID: 11406052
[TBL] [Abstract][Full Text] [Related]
8. Daily variation in lung function in COPD patients with combined albuterol and ipratropium: results from a 4-week, randomized, crossover study.
Singh D; Zhu CQ; Sharma S; Church A; Kalberg CJ
Pulm Pharmacol Ther; 2015 Apr; 31():85-91. PubMed ID: 25197005
[TBL] [Abstract][Full Text] [Related]
9. Bronchodilator reversibility to low and high doses of terbutaline and ipratropium bromide in patients with chronic obstructive pulmonary disease.
Newnham DM; Dhillon DP; Winter JH; Jackson CM; Clark RA; Lipworth BJ
Thorax; 1993 Nov; 48(11):1151-5. PubMed ID: 8296260
[TBL] [Abstract][Full Text] [Related]
10. Acute bronchodilator trials in chronic obstructive pulmonary disease.
Nisar M; Earis JE; Pearson MG; Calverley PM
Am Rev Respir Dis; 1992 Sep; 146(3):555-9. PubMed ID: 1387772
[TBL] [Abstract][Full Text] [Related]
11. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD.
Dorinsky PM; Reisner C; Ferguson GT; Menjoge SS; Serby CW; Witek TJ
Chest; 1999 Apr; 115(4):966-71. PubMed ID: 10208193
[TBL] [Abstract][Full Text] [Related]
12. Effects of high-dose ipratropium bromide and oral aminophylline on spirometry and exercise tolerance in COPD.
Shivaram U; Cash ME; Mateo F; Shim C
Respir Med; 1997 Jul; 91(6):327-34. PubMed ID: 9282234
[TBL] [Abstract][Full Text] [Related]
13. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease.
Rennard SI; Anderson W; ZuWallack R; Broughton J; Bailey W; Friedman M; Wisniewski M; Rickard K
Am J Respir Crit Care Med; 2001 Apr; 163(5):1087-92. PubMed ID: 11316640
[TBL] [Abstract][Full Text] [Related]
14. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Dutch Study Group.
Maesen FP; Smeets JJ; Sledsens TJ; Wald FD; Cornelissen PJ
Eur Respir J; 1995 Sep; 8(9):1506-13. PubMed ID: 8575576
[TBL] [Abstract][Full Text] [Related]
15. Does the mode of inhalation affect the bronchodilator response in patients with severe COPD?
Eiser NM; Phillips C; Wooler PA
Respir Med; 2001 Jun; 95(6):476-83. PubMed ID: 11421505
[TBL] [Abstract][Full Text] [Related]
16. Anticholinergic versus beta 2-agonist on gas exchange in COPD: a comparative study in 15 patients.
Pillet O; Manier G; Castaing Y
Monaldi Arch Chest Dis; 1998 Feb; 53(1):3-8. PubMed ID: 9632900
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic equivalence of a fenoterol/ipratropium bromide combination (Berodual) inhaled as a dry powder and by metered dose inhaler in chronic obstructive airway disease.
Rammeloo RH; Luursema PB; Sips AP; Beumer HM; Wald FD; Cornelissen PJ
Respiration; 1992; 59(6):322-6. PubMed ID: 1488568
[TBL] [Abstract][Full Text] [Related]
18. Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD.
Tashkin DP; Li N; Halpin D; Kleerup E; Decramer M; Celli B; Elashoff R
Respir Med; 2013 Dec; 107(12):1904-11. PubMed ID: 23972968
[TBL] [Abstract][Full Text] [Related]
19. Acute effects of higher than standard doses of salbutamol and ipratropium on tiotropium-induced bronchodilation in patients with stable COPD.
Cazzola M; Santus P; D'Adda A; Pizzolato S; Di Marco F; Centanni S
Pulm Pharmacol Ther; 2009 Jun; 22(3):177-82. PubMed ID: 19038356
[TBL] [Abstract][Full Text] [Related]
20. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study.
Anthonisen NR; Connett JE; Kiley JP; Altose MD; Bailey WC; Buist AS; Conway WA; Enright PL; Kanner RE; O'Hara P
JAMA; 1994 Nov; 272(19):1497-505. PubMed ID: 7966841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
